266 related articles for article (PubMed ID: 29549157)
41. Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor.
Yano H; Chitsazi R; Lucaj C; Tran P; Hoffman AF; Baumann MH; Lupica CR; Shi L
ACS Chem Neurosci; 2023 Nov; 14(21):3928-3940. PubMed ID: 37847546
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of cannabimimetic effects of selected minor cannabinoids and Terpenoids in mice.
Wiley JL; Marusich JA; Blough BE; Namjoshi O; Brackeen M; Akinfiresoye LR; Walker TD; Prioleau C; Barrus DG; Gamage TF
Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jun; 132():110984. PubMed ID: 38417478
[TBL] [Abstract][Full Text] [Related]
43. Combination Chemistry: Structure-Activity Relationships of Novel Psychoactive Cannabinoids.
Wiley JL; Marusich JA; Thomas BF
Curr Top Behav Neurosci; 2017; 32():231-248. PubMed ID: 27753007
[TBL] [Abstract][Full Text] [Related]
44. The next generation of synthetic cannabinoids: Detection, activity, and potential toxicity of pent-4en and but-3en analogues including MDMB-4en-PINACA.
Krotulski AJ; Cannaert A; Stove C; Logan BK
Drug Test Anal; 2021 Feb; 13(2):427-438. PubMed ID: 32997377
[TBL] [Abstract][Full Text] [Related]
45. In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs.
Deventer MH; Persson M; Norman C; Liu H; Connolly MJ; Daéid NN; McKenzie C; Gréen H; Stove CP
Drug Test Anal; 2024 Jun; 16(6):616-628. PubMed ID: 37903509
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.
Wiley JL; Lefever TW; Marusich JA; Grabenauer M; Moore KN; Huffman JW; Thomas BF
Neuropharmacology; 2016 Nov; 110(Pt A):143-153. PubMed ID: 27449567
[TBL] [Abstract][Full Text] [Related]
47. Linking in vitro and ex vivo CB
Janssens LK; Hudson S; Wood DM; Wolfe C; Dargan PI; Stove CP
Arch Toxicol; 2022 Nov; 96(11):2935-2945. PubMed ID: 35962200
[TBL] [Abstract][Full Text] [Related]
48. Δ(9)-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids in mice and rats.
Gatch MB; Forster MJ
Psychopharmacology (Berl); 2016 May; 233(10):1901-10. PubMed ID: 26875756
[TBL] [Abstract][Full Text] [Related]
49. Focusing on the 5F-MDMB-PICA, 4F-MDMB-BICA synthetic cannabinoids and their primary metabolites in analytical and pharmacological aspects.
Dvorácskó S; Körmöczi T; Sija É; Bende B; Weiczner R; Varga T; Ilisz I; Institóris L; Kereszty ÉM; Tömböly C; Berkecz R
Toxicol Appl Pharmacol; 2023 Jul; 470():116548. PubMed ID: 37182749
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics and pharmacodynamics of the synthetic cannabinoid, 5F-MDMB-PICA, in male rats.
Krotulski AJ; Garibay N; Walther D; Walton SE; Mohr ALA; Logan BK; Baumann MH
Neuropharmacology; 2021 Nov; 199():108800. PubMed ID: 34547333
[TBL] [Abstract][Full Text] [Related]
51. The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice.
Trexler KR; Vanegas SO; Poklis JL; Kinsey SG
Drug Alcohol Depend; 2020 Sep; 214():108179. PubMed ID: 32688070
[TBL] [Abstract][Full Text] [Related]
52. In vitro activity profiling of Cumyl-PEGACLONE variants at the CB
Janssens L; Cannaert A; Connolly MJ; Liu H; Stove CP
Drug Test Anal; 2020 Sep; 12(9):1336-1343. PubMed ID: 32490586
[TBL] [Abstract][Full Text] [Related]
53. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
54. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.
Wiley JL; Marusich JA; Lefever TW; Grabenauer M; Moore KN; Thomas BF
Neuropharmacology; 2013 Dec; 75():145-54. PubMed ID: 23916483
[TBL] [Abstract][Full Text] [Related]
55. The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs.
Banister SD; Kevin RC; Martin L; Adams A; Macdonald C; Manning JJ; Boyd R; Cunningham M; Stevens MY; McGregor IS; Glass M; Connor M; Gerona RR
Drug Test Anal; 2019 Jul; 11(7):976-989. PubMed ID: 30838752
[TBL] [Abstract][Full Text] [Related]
56. Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice.
Vigolo A; Ossato A; Trapella C; Vincenzi F; Rimondo C; Seri C; Varani K; Serpelloni G; Marti M
Neuropharmacology; 2015 Aug; 95():68-82. PubMed ID: 25769232
[TBL] [Abstract][Full Text] [Related]
57. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB
Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX
Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572
[TBL] [Abstract][Full Text] [Related]
58. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.
Tai S; Fantegrossi WE
Curr Top Behav Neurosci; 2017; 32():249-262. PubMed ID: 28012093
[TBL] [Abstract][Full Text] [Related]
59. Identification of synthetic cannabinoids that were seized, consumed, or associated with deaths in Kuwait in 2018 using GC-MS and LC-MS-MS analysis.
Al-Matrouk A; Alqallaf M; AlShemmeri A; BoJbarah H
Forensic Sci Int; 2019 Oct; 303():109960. PubMed ID: 31550599
[TBL] [Abstract][Full Text] [Related]
60. Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ
Hoffman AF; Lycas MD; Kaczmarzyk JR; Spivak CE; Baumann MH; Lupica CR
Addict Biol; 2017 Mar; 22(2):390-399. PubMed ID: 26732435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
